Literature DB >> 31732370

Temporal Trends and Predictors of Thirty-Day Readmissions and Emergency Department Visits Following Total Knee Arthroplasty in Ontario Between 2003 and 2016.

Tayler D Ross1, Erind Dvorani2, Refik Saskin2, Amir Khoshbin3, Amit Atrey3, Sarah E Ward3.   

Abstract

BACKGROUND: Total knee arthroplasty (TKA) is the second most common surgery performed in Canada. Understanding and improving quality metrics associated with such high-volume procedures is of utmost importance to maximize value within the healthcare system, which is a balance between cost and quality. Although rates and predictors of hospital readmission and emergency department (ED) visits following TKA have previously been described in privatized healthcare settings, few studies have evaluated trends in length of stay (LOS), hospital readmissions, and ED visits following TKA in a universal single-payer system.
METHODS: Using data from a provincially held and validated registry, the Institute for Clinical and Evaluative Sciences, we undertook a review of all 205,152 TKAs performed in the province of Ontario, Canada, between 2003 and 2016. We determined temporal trends in utilization, LOS, readmissions, and ED visits and evaluated patient and provider predictors of hospital readmissions and ED visits using multivariate logistic regression modeling. We also grouped and described the most common reasons for readmission and ED visits based on the available International Classification of Diseases, Ninth Revision and Tenth Revision coding information.
RESULTS: LOS decreased significantly over the study period (P < .0001), from a median of 5 days (10th percentile 3 days, 90th percentile 8 days) in 2003 to a median of 3 days (10th percentile 2 days, 90th percentile 4 days) in 2016. All-cause 30-day readmissions did not change significantly over the study period, but the rate of ED visits increased significantly over time. Predictors of 30-day readmission following TKA included older age, male gender, lower income quartile, not having a postoperative visit with a primary care physician (PCP), increased comorbidities, longer LOS, urgent or revision surgery, admission to a teaching hospital, and discharge to an inpatient rehabilitation facility. Variables that predicted increased odds of an ED visit included older age, male gender, lower income quartile, not having a postop visit with a PCP, increasing comorbidities, year of surgery, longer LOS, and revision surgery. Admission to a teaching hospital and discharge to an inpatient rehabilitation facility showed a trend toward increased odds of an ED visit.
CONCLUSIONS: We identified a significant increase in ED visits following TKA in Ontario between 2003 and 2016, with no corresponding increase in hospital readmissions despite a significant temporal trend toward shorter LOS. Predictors of ED visits and readmissions were similar, including male gender, lower income, higher comorbidities, and lacking a PCP visit postoperatively. Increased rates of ED visits following TKA in Ontario represent a quality problem, as they are associated with increased cost to the public healthcare system without any substantial benefit. Interventions aimed at redirecting patients from the ED for minor postoperative concerns should be investigated, as this is likely to improve care by reducing costs, improving efficiency, and enhancing patient experience.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  30-day emergency department visits; 30-day readmissions; length of stay quality; outcomes; predictors; total knee arthroplasty

Year:  2019        PMID: 31732370     DOI: 10.1016/j.arth.2019.09.015

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  7 in total

1.  The Impact of Pre-Operative Healthcare Utilization on Complications, Readmissions, and Post-Operative Healthcare Utilization Following Total Joint Arthroplasty.

Authors:  Ashley E Creager; Andrew D Kleven; Ziynet Nesibe Kesimoglu; Austin H Middleton; Meaghan N Holub; Serdar Bozdag; Adam I Edelstein
Journal:  J Arthroplasty       Date:  2021-11-15       Impact factor: 4.757

2.  Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study.

Authors:  Alex C Spyropoulos; Dimitrios Giannis; Jessica Cohen; Suja John; Anne Myrka; Damian Inlall; Michael Qiu; Saydi Akgul; Roger J Hyman; Jason J Wang
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

3.  Improvement in fast-track hip and knee arthroplasty: a prospective multicentre study of 36,935 procedures from 2010 to 2017.

Authors:  Pelle Baggesgaard Petersen; Henrik Kehlet; Christoffer Calov Jørgensen
Journal:  Sci Rep       Date:  2020-12-04       Impact factor: 4.379

Review 4.  Patient-Related Risk Factors for Unplanned 30-Day Hospital Readmission Following Primary and Revision Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.

Authors:  Daniel Gould; Michelle M Dowsey; Tim Spelman; Olivia Jo; Wassif Kabir; Jason Trieu; James Bailey; Samantha Bunzli; Peter Choong
Journal:  J Clin Med       Date:  2021-01-02       Impact factor: 4.241

Review 5.  Serious adverse events and 30-day hospital readmission rate following elective total knee arthroplasty: a systematic review and meta-analysis.

Authors:  Costas Papakostidis; Peter V Giannoudis; J Tracy Watson; Robert Zura; R Grant Steen
Journal:  J Orthop Surg Res       Date:  2021-03-31       Impact factor: 2.359

6.  Does Risk Mitigation Reduce 90-Day Complications in Patients Undergoing Total Knee Arthroplasty?: A Cohort Study.

Authors:  Vikas Kulshrestha; Munish Sood; Santhosh Kumar; Nikhil Sood; Pradeep Kumar; Prashanth P Padhi
Journal:  Clin Orthop Surg       Date:  2022-01-14

7.  Emergency department visits following total joint arthroplasty: do revisions present a higher burden?

Authors:  Vivek Singh; Utkarsh Anil; Mark Kurapatti; Joseph X Robin; Ran Schwarzkopf; Joshua C Rozell
Journal:  Bone Jt Open       Date:  2022-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.